Vontobel Holding Ltd. purchased a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 327,801 shares of the company's stock, valued at approximately $3,586,000. Vontobel Holding Ltd. owned 0.52% of Edgewise Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Edgewise Therapeutics by 29.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,833 shares of the company's stock valued at $228,000 after purchasing an additional 4,785 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Edgewise Therapeutics by 349.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,338 shares of the company's stock valued at $80,000 after purchasing an additional 5,704 shares during the period. SG Americas Securities LLC raised its position in shares of Edgewise Therapeutics by 59.5% in the fourth quarter. SG Americas Securities LLC now owns 29,826 shares of the company's stock valued at $326,000 after purchasing an additional 11,128 shares during the period. Vanguard Group Inc. raised its position in shares of Edgewise Therapeutics by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,064,421 shares of the company's stock valued at $11,829,000 after purchasing an additional 32,462 shares during the period. Finally, American Century Companies Inc. raised its position in shares of Edgewise Therapeutics by 1.4% in the third quarter. American Century Companies Inc. now owns 527,839 shares of the company's stock valued at $3,025,000 after purchasing an additional 7,337 shares during the period.
Analyst Ratings Changes
A number of research firms recently weighed in on EWTX. Truist Financial reaffirmed a "buy" rating and set a $25.00 target price on shares of Edgewise Therapeutics in a report on Wednesday. Piper Sandler began coverage on shares of Edgewise Therapeutics in a report on Thursday, March 7th. They set an "overweight" rating and a $48.00 target price on the stock. Finally, Wedbush reaffirmed an "outperform" rating and set a $26.00 target price on shares of Edgewise Therapeutics in a report on Tuesday.
Check Out Our Latest Research Report on Edgewise Therapeutics
Edgewise Therapeutics Price Performance
EWTX stock traded down $0.20 during midday trading on Thursday, reaching $15.45. The company had a trading volume of 531,462 shares, compared to its average volume of 945,039. Edgewise Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.69. The company has a market capitalization of $1.44 billion, a P/E ratio of -9.78 and a beta of 0.14. The firm has a 50-day moving average price of $17.13 and a 200-day moving average price of $11.93.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.03). On average, equities analysts predict that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current year.
Insiders Place Their Bets
In other news, General Counsel John R. Moore sold 8,029 shares of the company's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $20.01, for a total value of $160,660.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Behrad Derakhshan sold 4,600 shares of the company's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $20.01, for a total value of $92,046.00. Following the completion of the sale, the insider now owns 7,020 shares of the company's stock, valued at approximately $140,470.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel John R. Moore sold 8,029 shares of the company's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $20.01, for a total transaction of $160,660.29. The disclosure for this sale can be found here. Insiders sold a total of 120,622 shares of company stock valued at $2,032,766 in the last quarter. Corporate insiders own 31.95% of the company's stock.
About Edgewise Therapeutics
(
Free Report)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Recommended Stories
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
